DocGo Inc. (NASDAQ:DCGO) Given Average Recommendation of “Buy” by Brokerages

Shares of DocGo Inc. (NASDAQ:DCGO) have earned a consensus rating of “Buy” from the five analysts that are currently covering the company, Marketbeat reports. Five investment analysts have rated the stock with a buy recommendation. The average 12 month price target among analysts that have covered the stock in the last year is $7.75.

A number of equities analysts have commented on the company. BTIG Research lowered their price objective on DocGo from $11.00 to $7.00 and set a “buy” rating on the stock in a research note on Thursday, May 9th. Stifel Nicolaus lowered their price objective on DocGo from $8.00 to $6.50 and set a “buy” rating on the stock in a research note on Tuesday, April 30th. Cantor Fitzgerald lowered their price objective on DocGo from $11.00 to $5.00 and set an “overweight” rating on the stock in a research note on Thursday, May 9th. Needham & Company LLC lowered their price objective on DocGo from $10.00 to $7.00 and set a “buy” rating on the stock in a research note on Thursday, May 9th. Finally, Canaccord Genuity Group lowered their price objective on DocGo from $9.00 to $5.00 and set a “buy” rating on the stock in a research note on Thursday, May 9th.

DocGo Trading Down 6.6 %

Shares of NASDAQ DCGO opened at $3.25 on Friday. The firm has a market cap of $330.10 million, a P/E ratio of 16.25, a price-to-earnings-growth ratio of 1.74 and a beta of 0.91. DocGo has a 1-year low of $2.75 and a 1-year high of $10.82. The business’s 50 day moving average is $3.14 and its 200-day moving average is $3.42.

DocGo (NASDAQ:DCGO) last announced its earnings results on Wednesday, May 8th. The company reported $0.09 earnings per share for the quarter, hitting analysts’ consensus estimates of $0.09. The company had revenue of $192.09 million for the quarter, compared to analyst estimates of $185.36 million. DocGo had a return on equity of 6.20% and a net margin of 2.98%. Analysts forecast that DocGo will post 0.24 EPS for the current year.

Insider Activity

In other DocGo news, CEO Lee Bienstock purchased 25,000 shares of the firm’s stock in a transaction dated Monday, May 13th. The shares were bought at an average price of $3.15 per share, for a total transaction of $78,750.00. Following the purchase, the chief executive officer now owns 1,220,845 shares in the company, valued at approximately $3,845,661.75. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. In other news, CEO Lee Bienstock acquired 25,000 shares of the business’s stock in a transaction that occurred on Monday, May 13th. The shares were bought at an average price of $3.15 per share, with a total value of $78,750.00. Following the acquisition, the chief executive officer now directly owns 1,220,845 shares in the company, valued at approximately $3,845,661.75. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, General Counsel Ely D. Tendler acquired 10,000 shares of the business’s stock in a transaction that occurred on Monday, May 13th. The shares were purchased at an average cost of $3.13 per share, for a total transaction of $31,300.00. Following the acquisition, the general counsel now owns 162,933 shares in the company, valued at $509,980.29. The disclosure for this purchase can be found here. Corporate insiders own 2.70% of the company’s stock.

Institutional Investors Weigh In On DocGo

Several hedge funds have recently modified their holdings of the company. AJOVista LLC acquired a new stake in shares of DocGo during the 4th quarter valued at $25,000. nVerses Capital LLC lifted its holdings in DocGo by 151.5% during the 2nd quarter. nVerses Capital LLC now owns 8,300 shares of the company’s stock worth $26,000 after buying an additional 5,000 shares during the period. Nisa Investment Advisors LLC lifted its holdings in DocGo by 693.2% during the 2nd quarter. Nisa Investment Advisors LLC now owns 12,089 shares of the company’s stock worth $37,000 after buying an additional 10,565 shares during the period. Tower Research Capital LLC TRC lifted its holdings in DocGo by 181.8% during the 4th quarter. Tower Research Capital LLC TRC now owns 16,646 shares of the company’s stock worth $93,000 after buying an additional 10,738 shares during the period. Finally, Gladius Capital Management LP acquired a new position in DocGo during the 2nd quarter worth about $34,000. Institutional investors and hedge funds own 56.44% of the company’s stock.

DocGo Company Profile

DocGo Inc provides mobile health and medical transportation services for various health care providers in the United States and the United Kingdom. The company's transportation services include emergency response services; and non-emergency transport services comprise ambulance and wheelchair transportation services.